Recently, a bi-specific molecule which targets simultaneously CTLA-4 and TGF-β (a-CTLA4-TGFβRII) has been tested in preclinical models of adult solid tumors, showing an increased anti-tumor activity as compared to drugs targeting CTLA-4 alone, due to Treg inhibition [144]. This evidence concerns the gene CTLA4 and neoplasm.